Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen, WuXi AppTec Forge Biomarker Partnership

NEW YORK (GenomeWeb News) – Shanghai-based biotech firm WuXi AppTec said today that it will partner with Qiagen to develop an integrated biomarker service, as well as new biomarkers and assays.

Under the agreement, Qiagen will provide tools, training, and consumables, while WuXi will contribute its Shanghai lab facilities and staff to conduct the biomarker services. The lab is scheduled to begin operating immediately.

The firms also will work together to develop biomarkers, assay panels, diagnostics, and other products that Qiagen will market. WuXi said that it will use Qiagen's tools in a range of drug development and discovery services, which will be offered to both companies' customers.

Victor Shi, president of Qiagen's Asia Pacific operations, said in a statement that the partnership will create "the first laboratory of its kind in Asia equipped with a standardized, fully integrated, automated sample and assay technology platform for drug discovery and development and molecular diagnostics in personalized healthcare and other areas."

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.